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ABSTRACT
Telomerase/telomere-targeting therapy is a potentially promising approach 
for cancer treatment because even transient telomere dysfunction can induce 
chromosomal instability (CIN) and may be a barrier to tumor growth. We recently 
developed a dual-HAC (Human Artificial Chromosome) assay that enables identification 
and ranking of compounds that induce CIN as a result of telomere dysfunction. This 
assay is based on the use of two isogenic HT1080 cell lines, one carrying a linear HAC 
(containing telomeres) and the other carrying a circular HAC (lacking telomeres). 
Disruption of telomeres in response to drug treatment results in specific destabilization 
of the linear HAC. Results: In this study, we used the dual-HAC assay for the analysis 
of the platinum-derived G4 ligand Pt-tpy and five of its derivatives: Pt-cpym, Pt-
vpym, Pt-ttpy, Pt(PA)-tpy, and Pt-BisQ. Our analysis revealed four compounds, Pt-
tpy, Pt-ttpy, Pt-vpym and Pt-cpym, that induce a specific loss of a linear but not a 
circular HAC. Increased CIN after treatment by these compounds correlates with the 
induction of double-stranded breaks (DSBs) predominantly localized at telomeres 
and reflecting telomere-associated DNA damage. Analysis of the mitotic phenotypes 
induced by these drugs revealed an elevated rate of chromatin bridges (CBs) in late 
mitosis and cytokinesis. These terpyridine platinum-derived G4 ligands are promising 
compounds for cancer treatment.
INTRODUCTION
Normal human somatic cells contain 46 
chromosomes. A distinguishing feature of many cancer 
cells is whole-chromosomal instability (CIN) manifested 
as unequal chromosome distribution during cell division. 
As a consequence, the number of chromosomes deviates 
from the modal number of 46.  Such chromosome mis-
segregation can lead to large-scale changes in gene copy 
number and gene expression levels. 
Analysis of the consequences of induced increases 
in chromosome segregation errors on the viability of tumor 
cells led to the breakthrough discovery that chromosome 
mis-segregation may be exploited therapeutically 
[1]. That study revealed that there is a threshold level 
beyond which CIN becomes a barrier to tumor growth. 
Moreover, the authors reported that treatment with 
drugs that target the mitotic checkpoint or interfere with 
chromosome alignment enhances the amount and severity 
of chromosome segregation errors and leads to selective 
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killing of tumor cells. Subsequent studies confirmed 
that interference with chromosome segregation can push 
genetically unstable cancer cells towards death, whereas 
more stable non-transformed cells are better able to 
tolerate such insults [2–4].
Telomerase/telomere-targeting therapy is considered 
to be a potentially promising approach for cancer treatment 
[5–8] because even transient telomere dysfunction can 
induce chromosomal instability in human cells [9]. 
Telomeres are protein-DNA complexes located at the ends 
of eukaryotic chromosomes. They protect the DNA ends 
against exonucleases and ligases and prevent inappropriate 
chromosome end-to-end fusion [10]. Telomere length 
maintenance is required for long-term “healthy” division 
of cells. The enzyme telomerase elongates telomeres and 
maintains a telomere length equilibrium that prevents 
telomeres from becoming critically short [11]. Because 
telomeres contain G-rich repetitive sequences, they can 
form four-stranded structures called G-quadruplexes (G4s) 
[12–14]. A variety of data argues that such structures may 
have important effects on genomic stability [14, 15]. In 
particular, formation of G4s at telomeres could impede 
telomerase recognition and inhibit telomere elongation 
leading to telomere shortening [16, 17]. Excessively 
short telomeres no longer protect chromosome ends and 
cells undergo senescence or apoptosis [18–22]. However, 
till now only a limited number of chemical compounds 
that target telomerase or telomeres have been identified 
and only a few are in clinical trials. Thus, telomeres are 
promising targets for discovery of ligands that stabilize 
G4s at telomeres, thereby perturbing telomere maintenance 
and leading to genomic instability [23–27]. Such chemical 
compounds targeting G4 structures at telomeres could 
be potentially useful for anticancer therapy [7, 28–31]. 
Known G4 ligands include metal complexes that are 
promising compounds employed for cancer treatment 
[32–35]. 
Recently we developed a dual-HAC-based assay 
allowing quantitative comparison of the efficiency and 
specificity of compounds to induce telomere dysfunction 
[36]. This assay is based on the use of two cell lines, one of 
which carries a linear EGFP-expressing HAC (containing 
telomeres) [37]. The other carries a circular EGFP-
expressing HAC (lacking telomeres) [38] (Supplementary 
Figure 1). Compounds targeting telomeres should lead 
to selective destabilization of the linear HAC and loss 
of the EGFP signal (Figure 1). In contrast, compounds 
that destabilize both the linear and circular HACs are 
likely to have off-target effects in addition to any effect 
on telomeres (for example on kinetochores or the mitotic 
spindle). This dual-HAC assay was previously applied to 
analyze a set of compounds, including 19 G-quadruplex 
ligands, and identify those that specifically interfere with 
telomeres [36]. As a result, the compounds were ranked 
according to their potency at destabilizing the linear 
HAC. The assay revealed that two G4 stabilizing metal 
complexes, Cu-ttpy and Pt-ttpy, exhibited the highest rate 
of linear HAC mis-segregation [36]. We demonstrated an 
increased number of double-strand DNA breaks associated 
with telomeres after Cu-ttpy and Pt-ttpy treatment. This 
telomere damage led to the formation of chromosome 
bridges that ultimately resulted in chromosome mis-
segregation. 
In this study, we used the dual-HAC assay to analyze 
a larger set of platinum complexes comprising either a 
simple terpyridine moiety (Pt-tpy) or various terpyridine 
moieties with extended surface areas, i.e., Pt-ttpy, Pt-BisQ, 
Pt-vpym, Pt-cpym, and Pt(PA)-tpy [39]. It was shown 
previously that expanding the surface of the terpyridine 
core in this series of platinum complexes can both increase 
their affinity for telomeric G4s [40] and modulate their 
capacity to induce specific metalation of G4s in vitro 
[39]. However, it was not known how these structurally 
modified Pt-tpy derivatives would affect genomic stability. 
We have therefore explored the genomic activity of this 
expanded set of compounds in a more biologically relevant 
setting (the dual-HAC assay) and compared them to the 
previously studied Pt-ttpy derivative [36]. We found that 
treatment of cancer cells with either Pt-cpym, Pt-vpym, Pt-
ttpy or Pt-tpy induces telomere dysfunction leading to high 
levels of chromosome instability. Thus, these terpyridine 
platinum compounds potentially serve as onco-therapeutic 
agents for cancers. 
RESULTS
A dual-HAC assay revealed new platinum-derived 
G4 ligands that affect a linear HAC stability
In this work, we analyzed the platinum-derived 
G-quadruplex Pt-tpy ligand and five recently developed 
derivatives, i.e., Pt-cpym, Pt-vpym, Pt-ttpy, Pt(PA)-tpy, 
and Pt-BisQ [39]. Chemical structures of these terpyridine 
platinum compounds are shown in Figure 2A. We used 
the dual-HAC-based assay to determine how the various 
structural modifications alter the effects of the different 
Pt-tpy derivatives on chromosome stability. 
As previously demonstrated in other screens, the 
highest rate of HAC loss occurs at the compound’s LC50 
[41]. Thus, the LC50 provides a parameter to normalize 
the results from different drugs/compounds. Therefore, 
first we determined LC50 values for Pt-tpy, Pt-cpym, Pt-
vpym, Pt-ttpy, Pt(PA)-tpy, and Pt-BisQ. The results are 
shown in Supplementary Table 1. Figure 2B illustrates the 
effect of these compounds on the rate of loss of circular 
versus linear HACs.  As seen, no significant increase in 
loss of either HAC was detected for Pt(PA)-tpy and Pt-
BisQ. Worth noting is that the rather high cytoxicity of 
Pt(PA)-tpy limited its proper evaluation in cells. Four 
other compounds, Pt-cpym, Pt-vpym, Pt-ttpy and Pt-tpy 
exhibited strong effects on stability of the linear but not 
the circular HAC, comparable to that described earlier for 
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Pt-ttpy [36]. After treatment with those compounds, the 
rate of the linear HAC loss was almost 4-fold (Pt-cpym), 
11.8-fold (Pt-vpym), 7.7-fold (Pt-ttpy), and 6.4-fold (Pt-
tpy) higher than that observed in control cells containing 
the circular HAC (Figure 2B and Supplementary Table 2). 
Notably, four compounds have a similar square planar 
geometry due to platinum (II) tris-coordination to the 
terpyridine moiety (Figure 2A). This is in agreement with 
our previous observation that the planar shape resulting 
from the metal center geometry strongly influences the 
ability of metal-terpyridine complexes to discriminate 
quadruplex from duplex-DNA [40].
Thus, the dual-HAC assay allowed us to identify 
new compounds that potentially target telomeres and, 
therefore, are promising candidates for future development 
as therapeutic agents. We decided to investigate further the 
mechanism of action of Pt-cpym, Pt-vpym, Pt-ttpy, and 
Pt-tpy, as these exhibited the largest effects on linear HAC 
stability in cancer cells.
Treatment by Pt-cpym, Pt-vpym, Pt-ttpy, and Pt-
tpy leads to micronucleus formation
Micronuclei (MNi) are formed when chromosome 
fragments or whole chromosomes lag behind at anaphase 
during cell division and are not incorporated into the 
nucleus with the bulk of the segregated chromatids. MNi 
typically occur as a consequence of mutations or drug 
treatments that interfere with chromosome segregation. 
Thus, MNi scoring is a simple and rapid method to assess 
chromosome instability [42, 43]. We, therefore, used a 
micronucleus formation assay to evaluate if Pt-tpy and 
its derivatives Pt-cpym, Pt-vpym, and Pt-ttp affect the 
stability of natural chromosomes in human fibrosarcoma 
HT1080 cells. In our assay, we inhibited cytokinesis 
using cytochalasin B. This allowed us to conclude that 
binucleated cells had gone through mitosis during the 
period of drug treatment (see Materials and Methods 
for detail). Only binucleated cells were analyzed for the 
presence of MNi.
Concentrations of the compounds used in these 
experiments are presented in Supplementary Table 1. 
Our analysis revealed a significant difference in MNi 
formation between cells treated with the compounds 
versus untreated (DMSO-treated negative control cells) 
(Figure 3A, 3B and 3C and Supplementary Table 3). 
Data in Figure 3B are expressed in terms of percentages 
of the cells with MNi observed on the total number of 
binucleated cells analyzed and in terms of fold induction 
comparing treated versus untreated samples (DMSO). The 
percentage of MNi formation for Pt-cpym was 36% (95% 
CI 18–55%; 2.8-fold increase compared to the negative 
control), for Pt-vpym 28% (95% CI 19–38%, 2.2-fold 
increase), for Pt-ttpy 35% (95% CI 26–44%; 2.8-fold 
increase) and for Pt-tpy 37% (95% CI 34–39%; 2.9-fold 
increase), correspondingly. 
To summarize, MNi analysis confirmed that Pt-tpy 
and its derivatives have significant effects on the accuracy 
of mitotic transmission of the natural chromosomes. The 
elevated frequencies of binucleated cells with MNi support 
our assumption that these compounds have a potential to 
be used as therapeutic agents.
Treatment by Pt-cpym, Pt-vpym, Pt-ttpy, and Pt-
tpy induces chromatin bridges in late mitosis 
Formation of chromatin bridges is a sensitive 
measure of chromosome damage leading to chromosomal 
instability [44]. Chromatin bridges can form when 
telomeres of sister chromatids fuse and fail to completely 
segregate into the respective daughter cells [10]. 
Therefore, firstly, we scored the formation of CBs stained 
Figure 1: Experimental design for measuring CIN induced by telomere disfunction, based on the use of a linear EGFP-
HAC versus a circular EGFP-HAC. (A) Human fibrosarcoma HT1080 cells carried either the circular alphoidtetO-HAC [38] or the 
linear 21DqHAC [37]. Cells that inherit a HAC display green fluorescence, while cells that lack a HAC do not. Both HACs are stable during 
cell division. Therefore, the control cells without drug treatment display uniform green fluorescence while in the drug-treated population 
there is a mixture of EGFP positive and negative cells. (B) The actual percentage of cells carrying an EGFP-HAC was measured by FACS 
as previously described [36]. 
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with DAPI after mitosis. This is a relatively insensitive 
method that identifies only larger chromatin bridges. In 
these experiments, we observed no statistically significant 
increase in the percentage of cells showing CBs in cells 
treated with any of the drugs (Supplementary Figure 2 and 
Supplementary Table 3). 
To further analyze if thinner CBs appear in 
telophase, we used antibodies against LAP2, a nuclear 
envelope protein that decorates the chromatin (including 
chromatin bridges) from late anaphase onwards while 
it is still in the process of moving polewards. Because 
LAP2 coats the surface of any chromatin bridges during 
anaphase, it can render visible even bridges whose 
DNA content is too low to be seen by conventional 
DAPI staining. This experiment thus allows a more 
precise quantification of the frequency of CBs after drug 
treatment. Indeed, with LAP2 antibody, CBs were readily 
visible, even when they were too fine to be visualized by 
DAPI staining (Figure 4A). 
This analysis revealed a statistically significant 
difference in the frequency of CBs observed in drug-
treated cells versus untreated (DMSO) (Figure 4B and 
Supplementary Table 4). The percentage of CBs formation 
for Pt-cpym was 40% (95% CI 16–24%; 2.1-fold increase 
Figure 2: Effect of terpyridine platinum compounds on a linear versus a circular EGFP-HAC mis-segregation rate. (A) 
The chemical structures of Pt-tpy and its five derivatives Pt-cpym, Pt-vpym, Pt-ttpy, Pt(PA)-tpy, and Pt-BisQ; the terpyridine (tpy) core is 
shown in red and the aromatic surface expansion performed for each derivative is shown in blue. (B) HT1080 cells containing either a linear 
or a circular HAC were treated by Pt-tpy or its derivatives at concentrations corresponding to their LC50 (Supplementary Table 1) overnight. 
The rate of HAC loss was calculated based on the ratio of HAC-positive to HAC-negative cells as described in Materials and Methods. The 
controls correspond to the frequency of spontaneous loss of the linear or circular HAC in HT1080 cells. The highest rate of the linear HAC 
loss was observed after treatment by Pt-cpym, Pt-vpym, Pt-ttpy, and Pt-tpy. *Indicates P-value < 0.05; **P < 0.01.
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compared to the negative control), for Pt-vpym 37% (95% 
CI 25–49%, 1.9-fold increase), for Pt-ttpy 38% (95% CI 
26–50%; 1.9-fold increase) and for Pt-tpy 35% (95% CI 
25–45%; 1.8-fold increase). This increase in chromatin 
bridges is consistent with disruption of telomere function.
Treatment by Pt-cpym, Pt-vpym, Pt-ttpy, and 
Pt-tpy leads to an increased number of double-
stranded breaks that colocalize with telomeric 
markers 
To investigate further the mechanism(s) by 
which treatment with these drugs leads to chromosome 
instability, we stained HT1080 cells with an antibody 
against phosphorylated histone γH2AX to detect formation 
of DNA double-stranded breaks (DSBs). 
Concentrations of the compounds used in this 
experiment are presented in Supplementary Table 1. The 
number of DSBs were expressed in terms of the number of 
the γH2AX foci per nucleus and in terms of fold induction 
comparing treated versus untreated samples (DMSO). A 
statistically significant increase in the number of γH2AX 
foci in interphase was observed in cells after treatment 
with all four compounds (Figure 5A and Supplementary 
Table 5). The effect observed was as follows: Pt-cpym, 
51.1 foci/cell (95% CI 36.3–65.9 foci/cell; 9.6-fold 
increase) compared to the control level of DNA damage 
in HT1080 cells which was 5.3 foci/cell (95% CI 2.8–7.9 
foci/cell). After Pt-vpym treatment, there were 61.5 foci/
cell (95% CI 49–74 foci/cell; 11.6-fold increase). After Pt-
ttpy treatment there were 54.5 foci/cell (95% CI 39.3–69.7 
foci/cell; 10.3-fold increase). After Pt-tpy treatment, there 
were 59.9 foci/cell (95% CI 48.5–71.2 foci/cell; 11.3-fold 
increase). Thus, in HT1080 cells chromosome instability 
after treatment by Pt-cpym, Pt-vpym, Pt-ttpy, and Pt-tpy is 
accompanied by induction of DSBs.
We next examined whether the γH2AX foci co-
localize with or are adjacent to the telomeric protein 
TRF2 (telomeric repeat binding factor 2) in order to assess 
whether the DNA damage is associated with telomeric 
sequences. Previously we demonstrated that Pt-ttpy was 
incorporated into telomeres in vivo and caused DNA 
breaks [36]. Therefore, Pt-ttpy was used as an internal 
positive control in these experiments. Immunostaining 
with antibodies against TRF2 and γH2AX was carried 
out at day 3 (72 hrs) of drug treatment (see Materials and 
Methods). The level of telomere-specific DNA damage is 
expressed in terms of the frequency of the γH2AX foci 
Figure 3: Micronucleus formation in HT1080 cells after treatment by Pt-tpy and its three derivatives, Pt-cpym, Pt-
vpym and Pt-ttpy. (A) The percentage of binucleated cells without abnormalities. (B) The percentage of cells with MNi. Error bars 
correspond to the 95% confidence intervals (CI95%) of four replicates. Red asterisks indicate statistical significance when compared to 
the control [calculated using the two-tailed Student’s t-test with Bonferroni correction for multiple testing (*P < 0.05; **P < 0.01)]. (C) 
Representative images of a normal binucleated cell; binucleated cells containing MNi. White arrows point to MNi. The cells were stained 
with DAPI and Eosin Y. 
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that colocalize with telomere-specific TRF2 signals and in 
terms of fold induction comparing treated versus untreated 
samples (DMSO).
We observed that a 72 hrs treatment with any of the 
four compounds induced a statistically significant increase in 
co-localization of γH2AX foci with TRF2. The percentage 
of TRF2/γH2AX-positive foci in HT1080 increased from 
1.0% (95% CI 0.2–1.8%) in DMSO-treated negative control 
cells (spontaneous DNA damage) up to 11.5% (95% CI 
8.1–15%; 11.5-fold increase) in Pt-cpym-treated cells, 8.6% 
(95% CI 6.6–10.7%; 8.6-fold increase) in Pt-vpym-treated 
cells, 13.4% (95% CI 9.9–16.8%; 13.4-fold increase) in 
Pt-ttpy-treated cells and 13.8% (95% CI 11.3–16.5%; 13.8-
fold increase) in Pt-tpy-treated cells (Figure 5B and 5C 
and Supplementary Table 6). Since telomeric DNA only 
represents about 1/6,000th of the total genomic DNA, this 
increase above background is likely to be highly significant.
These data suggest that chromosome loss in Pt-
cpym, Pt-vpym, Pt-ttpy, and Pt-tpy treated cells may be 
a consequence of the induction of DSBs predominantly 
localized at or near telomeres. 
Treatment by Pt-cpym, Pt-vpym, Pt-ttpy, 
and Pt-tpy induces the formation of telomere 
aberrations 
Recombination events, which resolve replication 
fork collapse, can generate telomere aberrations such as 
telomere doublets (also named Multiple Telomeric Signals 
or MTSs), telomere fusions (also named Sister Chromatid 
Telomeric Fusions or SCTF), telomere loss and deletions. 
It has been reported that telomere doublets are linked to 
replicative defects of telomeres [45]. 
We analyzed HT1080 cells after treatment by 
Pt-cpym, Pt-vpym, Pt-ttpy, and Pt-tpy to ask whether 
treatment with these compounds was associated with 
increases in this class of chromosomal aberrations. For 
this purpose, metaphase spreads after 3 days of treatment 
Figure 4: Chromatin bridge formation in HT1080 cells after treatment by Pt-tpy and its three derivatives, Pt-cpym, 
Pt-vpym and Pt-ttpy at telophase/cytokinesis. (A) Cells after drug treatment were stained with antibodies against LAP2. LAP2 
allows visualization and quantification of fine chromatin bridges that are too thin to be spotted with DAPI staining. (B) The percentage 
of cells presenting chromatin bridges in telophase/cytokinesis upon treatment with Pt-cpym, Pt-vpym, Pt-ttpy, and Pt-tpy quantified using 
LAP2 as a marker.  *Indicates P-value < 0.05; **P < 0.01.
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were prepared and then labeled with a telomere specific 
PNA probe (see Materials and Methods for details) 
and counterstained with DAPI. Concentrations of the 
compounds used in these experiments are presented in 
Supplementary Table 1. Data are expressed in terms of 
frequencies of aberrations per metaphase analyzed and in 
terms of fold induction comparing treated versus untreated 
samples (DMSO).
FISH with the telomeric probe on metaphase 
spreads showed that Pt-cpym, Pt-vpym, Pt-ttpy, and 
Pt-tpy treatment induces a broad spectrum of telomeric 
aberrations (Figure 6A, 6D, 6E and Supplementary 
Figure 3). Total number of aberrations increased to 8.8 
per cell (95% CI 7.9–9.7 /cell; 2.1-fold increase) in Pt-
cpym-treated cells versus untreated cells (4.1 aberrations/
cell; 95% CI 3.8–4.5 /cell). After Pt-vpym treatment the 
number of aberrations was 9.9 per cell (95% CI 9.2–10.7 
/cell; 2.4-fold increase), after Pt-ttpy treatment 10.2 
aberrations per cell (95% CI 9.4–11.1 /cell; 2.5-fold 
increase), and after Pt-tpy treatment 9.6 aberrations per 
cell (95% CI 8.8–10.4 /cell; 2.3-fold increase) (Figure 6A 
and Supplementary Table 7). 
More specifically, the number of chromosomes 
with telomere doublets (TD) increased significantly after 
treatment with each of the four drugs studied (Figure 6B). 
While in the control DMSO-treated cells we observed 
2.1 TD per cell (95% CI 1.7–2.5 TD/cell), this number 
increased to 4.8 TD/cell (95% CI 3.9–5.7 TD/cell; 2.3-fold 
increase comparing to DMSO-treated cells) in Pt-cpym-
treated cells, 6 TD/cell (95% CI 5.4–6.7 TD/cell; 2.9-fold 
increase) in Pt-vpym-treated cells, 6 TD/cell (95% CI 5.2–
6.8 TD/cell; 2.9-fold increase) in Pt-ttpy-treated cells and 
5.6 TD/cell (95% CI 4.9–6.3 TD/cell; 2.7-fold increase) 
in Pt-tpy-treated cells (Figure 6B and Supplementary 
Table 7).
Single telomere loss (STL) increased significantly 
after Pt-cpym treatment to 3.4 STL/cell (95% CI 2.8–4 
STL/cell, 2.3-fold increase), after Pt-vpym treatment to 
3.4 STL/cell (95% CI 2.8–4 STL/cell; 2.3-fold increase), 
after Pt-ttpy to 3.5 STL/cell (95% CI 3–4.1 STL/cell, 
2.4–fold increase), and after Pt-tpy treatment to 3.4 STL/
cell (95% CI 2.7–4.1 STL/cell; 2.3-fold increase) relative 
to control cells (1.5 STL/cell; 95% CI 1.2–1.7 STL/cell) 
(Figure 6C and Supplementary Table 7).
Figure 5: Immunostaining of DNA double stranded breaks with an antibody against γH2AX and the telomeric protein 
TRF2. (A) The percentage of γH2AX foci in cells treated with Pt-tpy and its three derivatives, Pt-cpym, Pt-vpym and Pt-ttpy. Accumulation 
of γH2AX foci occurred at day 3 in all cases. (B) Co-localization of γH2AX foci with the telomeric protein TRF2. This panel shows the 
percentage of γH2AX foci present in the telomeric sequences. (C) Examples of immunostaining of cells treated with the compounds. Green 
signals – γH2AX staining as a marker for DSBs. White arrows point to cell nuclei with γH2AX signals. Red signals – TRF2 as a marker 
for telomere localization. A statistically significant co-localization of γH2AX foci and the TRF2 protein was observed at day 3 (t-test with 
Bonferroni correction: *P < 0.05; **P < 0.01) when compared to a negative control (DMSO) (Supplementary Table 6). 
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Telomere fusions and complete terminal deletions 
were the least frequent telomere aberrations and were not 
observed at significant levels in any of these experiments 
(Supplementary Figure 4 and Supplementary Table 7). 
DISCUSSION
Targeting telomerase and telomere maintenance 
mechanisms represents a promising therapeutic approach 
for various types of cancer [5, 6, 8]. However, assays 
comparing the efficiency and specificity of telomere-
targeted compounds were lacking. Moreover, the known 
compounds that target telomerase or telomeres are 
limited in number. To address this point, we have recently 
developed a novel assay allowing comparison of different 
compounds for their ability to induce telomere dysfunction 
leading to chromosome loss [36].
It is well known that even transient telomere 
dysfunction can induce CIN in human cells [9]. Therefore, 
the activity of each compound can be evaluated based on 
its effect on CIN. To quantify this effect, we used two 
isogenic fibrosarcoma HT1080 cell lines with linear and 
Figure 6: Specific telomere aberrations in HT1080 cells induced by treatment of Pt-tpy and its derivatives, Pt-cpym, 
Pt-vpym and Pt-ttpy. (A–C) Histograms show the percentages of chromosomes with the indicated telomere damage per cell detected in 
metaphase spreads of treated versus untreated cells (DMSO) hybridized with a telomeric PNA probe (in red) and then counterstained with 
DAPI (in blue). *Indicates a t-test P-value < 0.05; **P < 0.01. (D and E) Representative images of the different telomere aberrations after 
Pt-ttpy treatment. TD-telomere doublets; STL-single telomere loss; SCF-sister chromatid fusion; DEL-terminal deletion.
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circular HACs, each carrying an EGFP color marker. 
Specific destabilization of the linear HAC (containing 
telomeres) in response to drug treatment is consistent with 
specific targeting of telomeres. Conversely, destabilization 
of both linear and circular HACs indicates that a 
compound has off-target targets outside telomeres. 
In our previous work, we applied this dual-HAC 
assay to analyze G-quadruplex ligands. That study 
identified two metal complexes G4 compounds, Cu-ttpy 
and Pt-ttpy, that exhibited a significant capacity to target 
telomeres as assessed by their potency at destabilizing 
the linear HAC [36]. It is worth noting that this family of 
metal-terpyridine complexes displays higher affinity and 
selectivity towards telomeric G4s in vitro [40, 46, 47]. A 
typical feature of these Pt(II)-terpyridine derivatives is 
their capacity to crosslink telomeric G4s via the formation 
of monoadducts with the purine bases in the G4-loops 
[39, 48]. Moreover, in cells, these compounds have been 
shown to target telomeres via platinum coordination (i.e., 
crosslinking) to telomeric DNA [34]. Thus, the cellular 
activity profiles of these platinum–terpyridine G4 ligands 
are expected to result from a combination of G4 targeting 
and Pt(II) crosslinking at purine bases (G, A). 
In this study, we used the dual-HAC assay to analyze 
a series of six compounds, including the parent compound 
platinum-terpyridine Pt-tpy and five of its derivatives 
differing by the size of the aromatic terpyridine core [Pt-
cpym, Pt-vpym, Pt-ttpy, Pt(PA)-tpy, and Pt-BisQ]. Binding 
of these complexes to a panel of oligonucleotides (G4 of 
various topologies and duplex DNA) revealed a significant 
preference for telomeric G4 sequences [39]. Moreover, 
that in vitro study revealed that the size and structure of 
the terpyridine-like core modulate both the G4 binding 
capacity and the formation of Pt-purine crosslinks. For 
instance, Pt-BisQ and Pt(PA)-tpy show poor-to-no capacity 
for Pt-crosslinking due to steric hindrance of the Pt-BisQ 
moiety for the former and blockage of the Pt atom by the 
phenylacetylene (PA) moiety for the latter. Our analysis 
reveals that four of these compounds, Pt-cpym, Pt-vpym, 
Pt-ttpy, and Pt-tpy, induce specific destabilization of a 
linear HAC. Of note, the two derivatives mentioned above 
with hindered Pt-crosslinking do not display significant 
activity in the assay suggesting that Pt-crosslinking might 
contribute at least partially to the telomere-selective effect 
observed with the linear HAC. 
In our previous study we showed that for Pt-ttpy 
the telomere-selective effect was caused by specific 
targeting of telomeres that resulted in CIN [36]. Given the 
similar structure of the compounds studied here, a similar 
mechanism was proposed for Pt-cpym, Pt-vpym, and Pt-
tpy.  Indeed, after treatment of cells with these compounds, 
an increased number of DSBs at or near telomeres was 
observed. DSBs associated with telomeric sequences 
were confirmed by co-localization of γH2AX foci with 
the telomeric protein TRF2. Such telomere damage was 
proposed to lead to the formation of chromosome bridges 
in anaphase/telophase that we earlier observed for Pt-ttpy 
and Cu-ttpy [36], and ultimately resulted in chromosome 
mis-segregation. It is worth noting that we cannot exclude 
additional mechanisms of action for these G4 ligands, 
including transcriptional inactivation of genes important 
for chromosome segregation or induction of chromosomal 
DSBs as previously was described for other G4 stabilizers 
[49, 50].  
Importantly, concentrations corresponding to LC50 of 
all four active compounds are in the μM range suggesting 
that they could potentially overcome the cisplatin 
resistance common in cancer cells [39]. Moreover, these 
terpyridine-derived platinum G4 ligands exhibit promising 
radiosensitization properties in human glioblastoma and 
lung cancer cells at subtoxic doses [51]. 
In conclusion, using our dual-HAC assay we 
identified three terpyridine platinum compounds, Pt-
tpy, Pt-vpym and Pt-cpym, that induce a high level of 
chromosome instability (CIN) as previously reported 
for the related compound Pt-ttpy. CIN observed after 
treatment of cells with these compounds correlates with the 
formation of double-stranded DNA breaks predominantly 
localized proximal to telomeres. The telomere-associated 
DNA damage induced by these drugs leads to chromatin 
bridge formation in late mitosis and cytokinesis. This 
family of G4 ligands that induce telomere dysfunction and 
greatly increase chromosome mis-segregation rates are 
promising drug candidates for treatment of cancer alone 
or in combination with ionizing radiation. 
MATERIALS AND METHODS
Cell lines and culture
The human fibrosarcoma (HT1080; ATCC® CCL-
121™) cell line (telomerase positive) [36] obtained from the 
American Type Culture Collection was authenticated both 
morphologically and by short tandem repeat analysis. The 
cell line was tested regularly to confirm lack of mycoplasma 
infection using a mycoplasma detection kit from InvivoGen. 
The HT1080 cells harboring either a circular alphoidtetO-
HAC-EGFP [38] or a linear 21ΔqHAC-EGFP [37] were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
(Invitrogen) supplemented with 10% (v/v) fetal bovine 
serum (FBS, Clontech Laboratories, Inc.) at 37°C in a 5% 
CO2 atmosphere. For chromosome instability experiments, 
HT1080 cells were grown in medium containing 4 μg/ml 
Blasticidin S to prevent HAC loss prior to treatment with 
the drugs being tested (both linear and circular HACs 
contain the BS marker). After drug treatment, the cells 
were cultured in non-selective medium so that cells that 
have lost the HAC are able to grow. For mitotic abnormality 
experiments, the cells were not exposed to Blasticidin 
S because experiments were carried out in the parental 
HT1080 cell line with no HAC present.
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Compounds and treatments
Six different compounds [Pt-tpy and its five 
derivatives, Pt-cpym, Pt-vpym, Pt-ttpy, Pt(PA)-tpy, 
and Pt-BisQ], were used in our experiments. The 
experimental protocol was as previously described [36] 
(see details in Supplementary Materials). The compound 
concentration applied for measuring CIN was adjusted 
to the LC50 level for each compound. Concentrations of 
the compounds and lengths of treatments are presented 
in Supplementary Table 1. For each compound, the 
experiments on measuring EGFP-HAC loss were carried 
out in triplicate. The results were reproducible, and the 
standard deviations were small (for example, Pt-ttpy: SD 
± 0.2%). 
To study mitotic abnormalities induced by Pt-
tpy and its derivatives in the HT1080 cell line, we used 
much lower concentrations of the drugs as at the LC50 
only very small numbers of mitotic cells were seen.  For 
these experiments, the cells were treated by noncytotoxic 
drug concentrations at dose based on published data 
[39] and confirmed experimentally for our cell lines (see 
Supplementary Table 1). 
FISH analysis of EGFP-HACs  
The presence of the circular and linear HACs in 
an autonomous form was confirmed by FISH analysis 
as described previously [41, 52]. Metaphase cells were 
obtained by adding colcemid (Gibco) [36, 41].
Telomere fluorescent in situ hybridization (Telo-
FISH)
Metaphase spreads of drug-treated cells 
were prepared as described above and hybridized 
with a TelC-PNA telomere probe (Cy3-OO-
TAACCCTAACCCTAACCC; PNA BIO). Slides were 
mounted with Vectashield® Vibrance™ mounting media 
with DAPI and observed using a DeltaVision Elite 
imaging system. Z stacks were taken at 150 nm intervals 
and deconvolved. Images were analyzed with ImageJ 
software. Telomere aberrations scored were the following: 
telomere doublets, sister telomere losses, sister telomere 
fusions, terminal deletions. The numbers of metaphases 
analyzed in Telo-FISH experiments are reported in 
Supplementary Table 8.
Flow cytometry
Analysis of EGFP intensities encoded by the HACs 
was performed by flow cytometry on a FACSCalibur 
instrument (BD Biosciences) using CellQuest acquisition 
software and analyzed statistically with FlowJo software. 
The cells were harvested by trypsin-treatment. A minimum 
of 4 × 104 cells was analyzed for each cell sample.
Calculation of the rate of spontaneous HAC loss 
and after compound treatment
The rate of HAC loss after cell treatment by a single 
dose of drug was calculated as previously described [41] 
(see details in Supplementary Materials). 
Cell viability test for measuring HAC loss in 
response to drug treatment
The LC50 for each compound was obtained as 
previously described [36] (Supplementary Table 1) (see 
details in Supplementary Materials). Experiments were 
carried out in triplicate for each drug. 
Cytokinesis-block micronucleus assay
Cytokinesis-block micronucleus formation 
assays were performed as described [53] with minor 
changes. After 72 hrs of cultivation, Cytochalasin B 
was added to a final concentration of 4.5 μg/ml for 24 
hrs. The cells were trypsinized and 5 × 103 cells were 
centrifuged onto cytoslides (Shandon, # 5991056) at 
1,000 rpm for 1 min in a Cytospin 3 (Shandon). The 
slides were air-dried for 5 min, fixed with Diff-Quick 
fixative for 5 min, stained in Diff-Quick solution C 
(Eosin Y) (Electron Microscopy Sciences, # 26096) for 
10 seconds, rinsed in distilled water and dried for 5 min. 
Coverslips were mounted with Vectashield® Vibrance™ 
mounting media containing DAPI. Three slides from 
three independent treatments were prepared for each 
drug and for control vehicle treatment. The number of 
binucleated cells on each slide was scored along with 
the presence of micronuclei (MNi) or chromatin bridges 
(CBs) (Supplementary Table 8). 
Immunofluorescence
The number of γH2AX foci and the percentage 
of γH2AX foci associated with the telomeric sequences 
(identified by TRF2 staining) were calculated as 
previously described [36] (see details in Supplementary 
Materials). For each compound, 30 nuclei were analyzed 
(Supplementary Table 8).
For Figure 4 after drug treatment, the cells were 
fixed, permeabilized, and blocked as described above. The 
cells were stained with primary mouse monoclonal anti-
LAP2 antibody (BD Biosciences, catalog no. #611000, 
dilution 1:200). Fluorophore-conjugated secondary 
antibodies were goat-anti-mouse Alexa 488, dilution 
1:500 (Cell Signaling, catalog no. #4408S). The samples 
were mounted with Vectashield® Vibrance™ mounting 
media with DAPI. Microscope images were acquired on 
a DeltaVision Core system (Applied Precision). Z-series 
were collected with a spacing of 0.25 μm, and image 
stacks were subsequently deconvolved using SoftWorx. 
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Cells in telophase/cytokinesis were examined for the 
presence of chromatin bridges stained with DAPI and/or 
with LAP2.
Statistical analysis
The statistical significance of comparisons between 
multiple groups was determined by unpaired two-tailed 
Student’s t-test with Bonferroni correction. P values of 
less than 0.05 were considered statistically significant. 
The data are presented in diagrams as mean, error bars 
correspond to 95% confidence interval. In all experiments, 
bars compare results of untreated cells (DMSO) with drug-
treated cells. 
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